HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arden Q1

This article was originally published in The Rose Sheet

Executive Summary

Firm revisits its fiscal 2009 guidance for the first half and full year; sales are now expected to increase by 1% to 3.5% over first six months and 6.5% to 8.5% for the full year, Elizabeth Arden notes Nov. 6 in its first-quarter earnings release. Adjustment is due to challenging consumer and retail environment and the impact of foreign currency translations, firm says. Sales for the first quarter totaled $2.84.2 mil., up 4.6% versus the prior year. Sales were driven by new launches including Juicy Couture, Usher, Mariah Carey and Rocawear 9IX fragrances. Firm also introduced Prevage Body in the first quarter, which led to a 27% increase in sales for the Prevage anti-aging skin care franchise, according to Chairman, President and CEO E. Scott Beattie. Liz Claiborne brands also contributed to revenue gains (1"The Rose Sheet" June 2, 2008, In Brief)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel